Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of IN8bio's INB-400?
INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM)....
Data Insights
INB-400 by IN8bio for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
INB-400 is under clinical development by IN8bio and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...